ARS Pharmaceuticals Inc. (SPRY)
11.48
0.12 (1.06%)
At close: Jan 15, 2025, 12:39 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -54.37M | -34.68M | -20.24M | -1.06M | -23.97M | -17.58M |
| Depreciation & Amortization | 73.00K | 319.00K | 6.00K | 6.00K | 1.55M | 1.42M |
| Stock-Based Compensation | 9.23M | 5.84M | 2.83M | 3.54M | n/a | n/a |
| Other Working Capital | -4.55M | -2.47M | -6.39M | 4.67M | -714.00K | -946.00K |
| Other Non-Cash Items | -6.88M | 1.20M | 207.00K | 121.00K | -699.00K | 2.04M |
| Deferred Income Tax | n/a | n/a | -4.00K | 1K | n/a | n/a |
| Change in Working Capital | -7.33M | -12.75M | -356.00K | 6.46M | 3.30M | -433.00K |
| Operating Cash Flow | -59.27M | -40.08M | -17.56M | 9.07M | -18.90M | -16.88M |
| Capital Expenditures | -175.00K | -199.00K | -55.00K | -917.00K | -96.00K | -449.00K |
| Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -272.00M | n/a | -65.11M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 185.00M | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | n/a | 65.11M | n/a | n/a | n/a |
| Investing Cash Flow | -87.18M | -199.00K | -55.00K | -917.00K | -96.00K | -449.00K |
| Debt Repayment | n/a | -8.68M | -1.82M | 5.00M | 8.59M | -852.00K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 6.90M | 199.41M | 54.98M | 99.00K | n/a | n/a |
| Financial Cash Flow | 6.90M | 190.73M | 53.16M | 5.10M | 8.61M | 19.40M |
| Net Cash Flow | -139.55M | 150.46M | 35.54M | 14.17M | -10.18M | 2.08M |
| Free Cash Flow | -59.44M | -40.28M | -17.62M | 8.15M | -18.99M | -17.32M |